43,300 Shares in Vistagen Therapeutics Inc (NASDAQ:VTGN) Purchased by Wells Fargo & Company MN
Wells Fargo & Company MN purchased a new position in shares of Vistagen Therapeutics Inc (NASDAQ:VTGN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 43,300 shares of the company’s stock, valued at approximately $31,000.
Separately, Sphera Funds Management LTD. increased its position in Vistagen Therapeutics by 37.2% during the first quarter. Sphera Funds Management LTD. now owns 2,022,066 shares of the company’s stock worth $2,588,000 after acquiring an additional 548,148 shares during the period. 7.54% of the stock is owned by hedge funds and other institutional investors.
VTGN has been the topic of a number of recent research reports. Maxim Group set a $4.00 price target on shares of Vistagen Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 8th. Chardan Capital reiterated a “neutral” rating on shares of Vistagen Therapeutics in a research note on Monday, July 29th. ValuEngine upgraded shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, William Blair reiterated a “buy” rating on shares of Vistagen Therapeutics in a research note on Wednesday, October 9th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $3.57.
Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Friday, August 16th. The company reported ($0.15) earnings per share (EPS) for the quarter. On average, analysts expect that Vistagen Therapeutics Inc will post -1.26 earnings per share for the current fiscal year.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Read More: What is Put Option Volume?
Want to see what other hedge funds are holding VTGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vistagen Therapeutics Inc (NASDAQ:VTGN).
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.